Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × lutetium Lu 177 dotatate × Endocrine × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 41 Observational 6 Expanded_access 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

3-Iodobenzylguanidine 6 surufatinib 1 selpercatinib 1 pegfilgrastim 1 lutetium Lu 177 dotatate 1 gallium Ga 68 dotatate 1 fluorodopa F 18 1 Vorinostat 1 Potassium Iodide 1 Granulocyte Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡